Comments on “Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses”

Comments on “Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses”

Bibliographic Details
Main Author:	Tom Greenfield
Format:	Article
Language:	English
Published:	Elsevier 2017-12-01
Series:	Genomics, Proteomics & Bioinformatics
Online Access:	http://www.sciencedirect.com/science/article/pii/S1672022917301353

Similar Items

Author’s Reply: Comments on “Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses”
by: Mou-Ze Liu, et al.
Published: (2017-12-01)

Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses
by: Hai-Yan He, et al.
Published: (2017-04-01)

Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
by: Ramón Cacabelos, et al.
Published: (2015-12-01)

Analysis of individual protein regions provides novel insights on cancer pharmacogenomics.
by: Eduard Porta Pardo, et al.
Published: (2015-01-01)

Pharmacogenomics And Hypertension: Current Insights
by: Oliveira-Paula GH, et al.
Published: (2019-11-01)

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
by: Stojiljkovic Maja, et al.
Published: (2012-09-01)

Encircling the regions of the pharmacogenomic landscape that determine drug response
by: Adrià Fernández-Torras, et al.
Published: (2019-03-01)

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
by: Hopewell, J, et al.
Published: (2014)

Pharmacogenomics in drug discovery and development /
by: Yan, Qing, 1971-
Published: (2008)

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
by: José A. G. Agúndez, et al.
Published: (2022-04-01)

Pharmacogenomics of intravenous immunoglobulin response in Kawasaki disease
by: Sadeep Shrestha, et al.
Published: (2024-01-01)

Anti-platelet drugs, pharmacogenomics and stent thrombosis: What’s new?
by: John Benjamin
Published: (2017-04-01)

Pharmacogenomics of Cardiovascular Pharmacology: Pharmacogenomic Network of Cardiovascular Disease Models
by: Toshio Tanaka, et al.
Published: (2008-01-01)

Personalized Medicine: Pharmacogenomics and Drug Development
by: Somayeh Mirsadeghi, et al.
Published: (2017-03-01)

Pharmacogenomics and Adverse Drug Reactions in Children
by: Michael John Rieder, et al.
Published: (2014-04-01)

Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation
by: Stuart A. Scott, et al.
Published: (2021-03-01)

Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
by: Liang Li, et al.
Published: (2009-11-01)

Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation
by: Stefano Turolo, et al.
Published: (2023-07-01)

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics
by: Wei Zhang, et al.
Published: (2008-01-01)

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
by: Lally J, et al.
Published: (2016-11-01)

Can pharmacogenomics improve malaria drug policy?
by: Mary W Roederer, et al.

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
by: Ramón Cacabelos, et al.
Published: (2021-12-01)

Pharmacogenetics, pharmacogenomics and airway disease
by: Hall Ian P
Published: (2001-11-01)

Structure–activity relationships and interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm
by: Romany H. Thabet, et al.
Published: (2023-11-01)

Pharmacogenomics /
by: Kalow, Werner, et al.
Published: (2005)

Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis
by: Annie Wai Yeeng Chai, et al.
Published: (2021-12-01)

Pharmacogenomics of Lithium Response in Bipolar Disorder
by: Courtney M. Vecera, et al.
Published: (2021-03-01)

Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis
by: Verónica Yumiceba, et al.
Published: (2020-10-01)

Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals
by: Yang Wang, et al.
Published: (2021-11-01)

Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
by: Alfredo Mauriello, et al.
Published: (2023-11-01)

Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
by: Mo-Yun Li, et al.
Published: (2022-10-01)

Pharmacogenomics of Hypersensitivity to Non-steroidal Anti-inflammatory Drugs
by: Hoang Kim Tu Trinh, et al.
Published: (2021-06-01)

Research Progress of Pharmacogenomics in Drug-Induced Liver Injury
by: Qihui Shao, et al.
Published: (2021-09-01)

Growing impact of pharmacogenomic on drug development and personalized medicine
by: Mario Eandi
Published: (2008-01-01)

The Gene-Drug Duality: Exploring the Pharmacogenomics of Indigenous Populations
by: Shivashankar H. Nagaraj, et al.
Published: (2021-09-01)

Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods
by: Song Zhai, et al.
Published: (2022-09-01)

Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease
by: Theodora Katsila, et al.
Published: (2016-03-01)

Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics
by: Therdpong Tempark, et al.
Published: (2022-04-01)

When the same treatment has different response: The role of pharmacogenomics in statin therapy
by: Edward Zheng, et al.
Published: (2024-01-01)

Role of Pharmacogenomics in Statin Responsiveness; A Review
by: Niusha behdad, et al.
Published: (2015-12-01)